<unk>  is indicated to be used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain other processing-deficient progeroid laminopathies in people one year of age and older.
Lonafarnib
Tepotinib
Icotinib
Afatinib
Dabrafenib
Nilotinib
Lestaurtinib
Crizotinib